Anti-BRNP1/ BRINP1/ DBC1 functional antibody

Anti-BRNP1/ BRINP1/ DBC1 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to BRINP1/BRINP1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE1421-Ab-1/ GM-Tg-hg-SE1421-Ab-2Anti-Human BRINP1 monoclonal antibodyHuman
GM-Tg-rg-SE1421-Ab-1/ GM-Tg-rg-SE1421-Ab-2Anti-Rat BRINP1 monoclonal antibodyRat
GM-Tg-mg-SE1421-Ab-1/ GM-Tg-mg-SE1421-Ab-2Anti-Mouse BRINP1 monoclonal antibodyMouse
GM-Tg-cynog-SE1421-Ab-1/ GM-Tg-cynog-SE1421-Ab-2Anti-Cynomolgus/ Rhesus macaque BRINP1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE1421-Ab-1/ GM-Tg-felg-SE1421-Ab-2Anti-Feline BRINP1 monoclonal antibodyFeline
GM-Tg-cang-SE1421-Ab-1/ GM-Tg-cang-SE1421-Ab-2Anti-Canine BRINP1 monoclonal antibodyCanine
GM-Tg-bovg-SE1421-Ab-1/ GM-Tg-bovg-SE1421-Ab-2Anti-Bovine BRINP1 monoclonal antibodyBovine
GM-Tg-equg-SE1421-Ab-1/ GM-Tg-equg-SE1421-Ab-2Anti-Equine BRINP1 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE1421-Ab-1/ GM-Tg-hg-SE1421-Ab-2; GM-Tg-rg-SE1421-Ab-1/ GM-Tg-rg-SE1421-Ab-2;
GM-Tg-mg-SE1421-Ab-1/ GM-Tg-mg-SE1421-Ab-2; GM-Tg-cynog-SE1421-Ab-1/ GM-Tg-cynog-SE1421-Ab-2;
GM-Tg-felg-SE1421-Ab-1/ GM-Tg-felg-SE1421-Ab-2; GM-Tg-cang-SE1421-Ab-1/ GM-Tg-cang-SE1421-Ab-2;
GM-Tg-bovg-SE1421-Ab-1/ GM-Tg-bovg-SE1421-Ab-2; GM-Tg-equg-SE1421-Ab-1/ GM-Tg-equg-SE1421-Ab-2
Products NameAnti-BRINP1 monoclonal antibody
Formatmab
Target NameBRINP1
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-BRINP1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE1421-Ag-1Recombinant multi-species BRNP1/ BRINP1/ DBC1 protein
    ORF Viral VectorpGMLP001609human BRINP1 Lentivirus plasmid
    ORF Viral VectorvGMLP001609human BRINP1 Lentivirus particle
    ORF Viral VectorpGMLPm003564mouse Brinp1 Lentivirus plasmid
    ORF Viral VectorvGMLPm003564mouse Brinp1 Lentivirus particle


    Target information

    Target IDGM-SE1421
    Target NameBRINP1
    Gene ID1620,56710,140610,701794,481694,101085671,538990,100066915
    Gene Symbol and SynonymsBRINP,BRINP1,DBC1,DBCCR1,FAM5A
    Uniprot AccessionO60477,Q925T8,Q5E9L2
    Uniprot Entry NameBRNP1_HUMAN,BRNP1_RAT,BRNP1_BOVIN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000078725
    Target ClassificationN/A

    The target: BRINP1, gene name: BRINP1, also named as DBC1, DBCCR1, FAM5A. This gene is located within a chromosomal region that shows loss of heterozygosity in some bladder cancers.  It contains a 5' CpG island that may be a frequent target of hypermethylation, and it may undergo hypermethylation-based silencing in some bladder cancers. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.